ImmunoGen, Inc. – NASDAQ:IMGN
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
ImmunoGen stock price monthly change
+4.48%
month
ImmunoGen stock price quarterly change
+111.87%
quarter
ImmunoGen stock price yearly change
+641.80%
year
ImmunoGen key metrics
Market Cap | 8.72B |
Enterprise value | 731.80M |
P/E | -4.25 |
EV/Sales | 6.72 |
EV/EBITDA | -3.39 |
Price/Sales | 9.11 |
Price/Book | 6.36 |
PEG ratio | 0.14 |
EPS | -0.30 |
Revenue | 287.61M |
EBITDA | -68.63M |
Income | -73.07M |
Revenue Q/Q | 637.72% |
Revenue Y/Y | 200.82% |
Profit margin | -204.93% |
Oper. margin | -203.06% |
Gross margin | 37.68% |
EBIT margin | -203.06% |
EBITDA margin | -23.86% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmunoGen stock price history
ImmunoGen stock forecast
ImmunoGen financial statements
| Dec 2022 | 41.16M | -59.00M | -143.34% |
|---|---|---|---|
| Mar 2023 | 49.86M | -40.56M | -81.35% |
| Jun 2023 | 83.15M | -4.24M | -5.11% |
| Sep 2023 | 113.42M | 30.74M | 27.11% |
| 2025 | 538.20M | 104.14M | 19.35% |
|---|---|---|---|
| 2026 | 757.20M | 258.47M | 34.14% |
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 348936000 | 193.11M | 55.34% |
|---|---|---|---|
| Mar 2023 | 288345000 | 166.42M | 57.72% |
| Jun 2023 | 714327000 | 223.48M | 31.29% |
| Sep 2023 | 822101000 | 260.50M | 31.69% |
| Dec 2022 | -60.19M | -248K | 26.07M |
|---|---|---|---|
| Mar 2023 | -73.71M | -209K | 39K |
| Jun 2023 | -66.74M | -78K | 437.55M |
| Sep 2023 | 2.77M | -1.35M | 32.13M |
ImmunoGen alternative data
| Aug 2023 | 277 |
|---|---|
| Sep 2023 | 277 |
| Oct 2023 | 277 |
| Nov 2023 | 277 |
| Dec 2023 | 277 |
| Jan 2024 | 277 |
| Feb 2024 | 277 |
| Mar 2024 | 277 |
| Apr 2024 | 277 |
| May 2024 | 277 |
| Jun 2024 | 277 |
| Jul 2024 | 277 |
ImmunoGen other data
93.34%
-2.11%
of IMGN is owned by hedge funds
201
-21
192.42M
+2.62M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 3340622 |
| Sep 2023 | 0 | 192013 |
| Oct 2023 | 0 | 192004 |
| Nov 2023 | 0 | 463607 |
| Dec 2023 | 0 | 123993 |
| Jan 2024 | 0 | 187667 |
| Feb 2024 | 0 | 39348 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | COEN STACY ANN officer: SVP & CH.. | Common Stock | 4,583 | $29.3 | $134,282 | ||
Sale | WINGROVE THERESA officer: SVP OF R.. | Common Stock | 12,027 | $29.3 | $352,391 | ||
Sale | ENYEDY MARK J director, officer.. | Common Stock | 20,107 | $29.28 | $588,733 | ||
Sale | LENTINI RENEE officer: VP & PRIN ACCTG OFFICER | Common Stock | 2,631 | $29.3 | $77,088 | ||
Option | COEN STACY ANN officer: SVP & CH.. | Common Stock | 14,350 | N/A | N/A | ||
Option | COEN STACY ANN officer: SVP & CH.. | Restricted Stock Unit | 14,350 | N/A | N/A | ||
Option | WINGROVE THERESA officer: SVP OF R.. | Common Stock | 126,100 | $5.25 | $662,025 | ||
Option | WINGROVE THERESA officer: SVP OF R.. | Common Stock | 2,667 | $5.75 | $15,335 | ||
Option | WINGROVE THERESA officer: SVP OF R.. | Common Stock | 58,900 | $4.83 | $284,487 | ||
Option | WINGROVE THERESA officer: SVP OF R.. | Stock Option (Right to Buy) | 126,100 | $5.25 | $662,025 |
| Patent |
|---|
Application Filling date: 8 Feb 2022 Issue date: 25 Aug 2022 |
Grant Filling date: 12 Aug 2020 Issue date: 23 Aug 2022 |
Grant Filling date: 1 Oct 2020 Issue date: 26 Jul 2022 |
Grant Filling date: 22 Oct 2020 Issue date: 19 Jul 2022 |
Application Filling date: 13 Dec 2021 Issue date: 30 Jun 2022 |
Application Filling date: 17 Feb 2022 Issue date: 2 Jun 2022 |
Application Filling date: 10 Nov 2021 Issue date: 2 Jun 2022 |
Application Filling date: 21 Jul 2021 Issue date: 26 May 2022 |
Grant Filling date: 22 Oct 2020 Issue date: 17 May 2022 |
Application Filling date: 31 Aug 2021 Issue date: 12 May 2022 |
| Quarter | Transcript |
|---|---|
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 31 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 28 Apr 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 1 Mar 2023 | Q4 2022 Earnings Call Transcript |
AbbVie: Get Ready For More Painful Downside
ImmunoGen: Elahere Data Mid-2024 To Expand Targeted Population
Analyzing The Acquisition Potential Of ImmunoGen
ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?
ImmunoGen's ELAHERE Has Likely Blockbuster Potential
ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential
ImmunoGen: Making A Successful Comeback
2 Regulatory Submissions Of ELAHERE In 2023 Make ImmunoGen A Must Watch
ImmunoGen's Elahere Breakthrough Offers Hope For Patients And Investors Alike
-
When is ImmunoGen's next earnings date?
Unfortunately, ImmunoGen's (IMGN) next earnings date is currently unknown.
-
Does ImmunoGen pay dividends?
No, ImmunoGen does not pay dividends.
-
How much money does ImmunoGen make?
ImmunoGen has a market capitalization of 8.72B.
-
What is ImmunoGen's stock symbol?
ImmunoGen, Inc. is traded on the NASDAQ under the ticker symbol "IMGN".
-
What is ImmunoGen's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ImmunoGen?
Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the following people:
- Mr. Mark Joseph Enyedy Pres, Chief Executive Officer & Director(age: 61, pay: $1,210,000)
- Dr. Anna Berkenblit Senior Vice President & Chief Medical Officer(age: 55, pay: $641,740)
- Dr. Theresa G. Wingrove Senior Vice President of Regulatory Affairs & Quality(age: 67, pay: $548,210)
- Ms. Susan Altschuller Ph.D. Senior Vice President & Chief Financial Officer(age: 43, pay: $391,210)
- Ms. Stacy A. Coen Senior Vice President & Chief Bus. Officer(age: 54, pay: $388,970)
-
How many employees does ImmunoGen have?
As Jul 2024, ImmunoGen employs 277 workers.
-
When ImmunoGen went public?
ImmunoGen, Inc. is publicly traded company for more then 35 years since IPO on 17 Nov 1989.
-
What is ImmunoGen's official website?
The official website for ImmunoGen is immunogen.com.
-
Where are ImmunoGen's headquarters?
ImmunoGen is headquartered at 830 Winter Street, Waltham, MA.
-
How can i contact ImmunoGen?
ImmunoGen's mailing address is 830 Winter Street, Waltham, MA and company can be reached via phone at +7 818950600.
ImmunoGen company profile:
ImmunoGen, Inc.
immunogen.comExchange:
NASDAQ
Full time employees:
277
Industry:
Biotechnology
Sector:
Healthcare
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
830 Winter Street
Waltham, MA 02451-1477
Waltham, MA 02451-1477
CIK: 0000855654
ISIN: US45253H1014
CUSIP: 45253H101
